Deferoxamine Mesylate for injection, USP, Single-use Vial, 500 mg/vial, 10 mL vial. Intravenous, Intramuscular, Subcutaneous Use, Rx Only, Hospira, Inc., Lake Forest IL USA, NDC 0406-2336-10.
Published October 11, 2017 · Recall initiated: July 12, 2017
Summary
FDA records drug Class III recall D-0001-2018, published October 11, 2017 and initiated July 12, 2017. Recalling firm: Pfizer Inc.; Status: Terminated; Reported quantity: 32,276 10 mL vials; Lot: Lot: 51275DD; Exp. 09/01/17. Class III means the product is not likely to cause adverse health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
CGMP Deviations: Firm failed to control impurity for color change at the API stage.
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Pfizer Inc.
- Distributor
- Nationwide
- Lot
- Lot: 51275DD; Exp. 09/01/17
- Risk classification
- Class III
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDABicillin L-A (penicillin G benzathine injectable suspension), 2,400,000 units per 4 mL, 4ml-vial, Rx Only,August 6, 2025
- FDABicillin L-A (penicllin G benzathine injectable suspension), 1,200,000 units per 2 mL, 2 mL-vial, Rx Only,August 6, 2025
- FDADOBUTamine Injection, USP, 250 mg/20 mL (12.5 mg/mL), 20 mL per Single-dose Vial, carton of 10 Fliptop Vials,July 2, 2025
- FDALabetalol Hydrochloride Injection, USP, 20 mg/4 mL (5 mg/mL), 4 mL Single-dose Carpuject, Sterile CartridgeJuly 3, 2024
- FDAOption Systems Antibacterial Foaming Hand Wash, 0.3% P.C.M.X., 8 fl oz and 18 fl oz. bottles and 500, mL 800October 11, 2017
- FDANOVADAQ SPY-PHI PAQ Intended for use with the SPY-PHI System, Product Code HH9006, containing 6October 4, 2017
Questions about this recall
Was Deferoxamine Mesylate for injection, USP, Single-use Vial, 500 mg/vial, 10 mL vial. Intravenous, Intramuscular, Subcutaneous Use, Rx Only, Hospira, Inc., Lake Forest IL USA, NDC 0406-2336-10. recalled?
Yes. FDA published recall D-0001-2018 on October 11, 2017. Reported hazard: CGMP Deviations: Firm failed to control impurity for color change at the API stage.
What should I do if I have this product?
Voluntary: Firm initiated · Letter